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A macrophage colony-stimulating factor (M-CSF) was purified to homogeneity from a large amount of 
normal human urine. Microanalysis of the N-terminal amino acid sequence up to residue 44 revealed only 
a single residue difference from that deduced by other workers from the nucleotide sequence of M-CSF 
cDNA clones. The amino acid composition of the present preparation suggested that the M-CSF which 
we purified possessed a structure fitting the sequence 1-190 of TPA30-1 cell M-CSF deduced by Wong et 
al. [(1987) Science 235, 1504-1508]. 
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1. INTRODUCTION 
Macrophage colony-stimulating factor (M-CSF, 
also called CSF-1) is a protein specifically required 
for proliferation and functions of cells of 
monocyte/macrophage lin age [1]. 
The total amino acid sequence of human M-CSF 
was deduced by Kawasaki et al. [2] as well as by 
Wong et al. [3] from the nucleotide sequence of 
complementary DNA (cDNA) clones derived from 
human tumor cell lines. The sequence deduced by 
Kawasaki et al. [2] is nearly consistent with that 
deduced by Wong et al. [3] between position 1 and 
position 148. However, the latter sequence con- 
tains an additional sequence of 295 residues in- 
tervening between position 148 and position 149 of 
the former. 
Kawasaki et al. [2] also determined the N- 
terminal 12 residues of human urine M-CSF and 
the N-terminal 30 residues of mouse L-cell M-CSF. 
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The sequence obtained by protein sequencing ex- 
actly matched that deduced from the analysis of 
cDNA insofar as the first 12 residues of human M- 
CSF were concerned. On the other hand, mouse L- 
cell M-CSF differed from human MIA-PaCa-2 M- 
CSF at six positions in the N-terminal region, 
which was confirmed recently by Boosman et al. 
[4]. 
Here, we purified an M-CSF from human urine 
and determined its N-terminal sequence up to posi- 
tion 44. Except for Ser at position 37, the N- 
terminal sequence we determined was consistent 
with that deduced by the two groups of workers 
mentioned above. On the other hand, analysis of 
the amine acid composition of our preparation 
showed considerable differences from that predic- 
table from the sequence deduced by Kawasaki et 
al. [21. 
2. MATERIALS AND METHODS 
2.1. Partial purification o f  M-CSF f rom normal 
human urine 
Proteins were adsorbed from fresh urine 
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(10400 1) on Tokusil UR (20 kg) (Tokuyama Soda, 
Tokyo), extracted from the adsorbent with 1070 
NH4OH and precipitated by (NH4)2SO4 at 8007o 
saturation. The precipitate was collected, dissolved 
in water, and heated at 60°C for 10 h at pH 4.5. 
Insoluble materials were removed by cen- 
trifugation. 
After desalting, the solution was applied to a 
25 × 32 cm column of DEAE-cellulofine AH 
(Seikagaku Kogyo, Tokyo) equilibrated with 
20 mM sodium phosphate buffer, pH 4.5. The 
bound proteins were eluted with 20 mM 
phosphate/300 mM NaCI, pH 4.5. The solution 
was desalted and placed on a DE52 (Whatman) 
column (9 x 90 cm) in 20 mM phosphate/30 mM 
NaCI/0.05% polyethylene glycol (PEG), pH 7.4. 
A linear NaC1 gradient (30-500 mM, 20 I) was ap- 
plied, and 5907o f the M-CSF activity eluted be- 
tween 120 and 160 mM NaC1. 
The M-CSF solution then was brought to I M 
(NH4)2SO4 and run in 225-ml portions on a 9 × 
53 cm column of phenyl-Sepharose CL-4B (Phar- 
macia) in 10 mM phosphate/0.15 M NaC1/0.05% 
PEG/1 M (NH4)2SO4, pH 7.4. The M-CSF activi- 
ty eluted between 0.8 and 0.6 M (NH4)2SO4 on a 
linear gradient of decreasing (NIq-4)2SO4 concen- 
tration (1.0-0 M) in phosphate/NaC1/PEG buffer 
(20 1). 
The solution was concentrated by ultrafiltration, 
and 60-ml aliquots were run on a Sephacryl $300 
(Pharmacia) column (9 x 90 cm) in 20 mM 
phosphate/0.15 M NaCl/0.05070 PEG, pH 7.4 
(PBS/PEG). The M-CSF eluted between 1.71 and 
1.84 void volumes. All of the procedures mention- 
ed above were carried out at 5°C. 
2.2. Final purification of M-CSF 
The above-mentioned preparation was further 
purified in 0.2-ml portions on a Pharmacia FPLC 
system equipped with two Superose-12 columns 
connected in series (10 × 600 ram). PBS/PEG buf- 
fer was used and 70070 of the M-CSF activity 
emerged as a peak from 1.45 to 1.56 void volumes. 
The M-CSF solution then was made 0.1% in 
tetrafluoroacetic acid (TFA) and loaded in aliquots 
(120/zg) on a/~-Bondapak ClS column (Waters) 
(3.9 × 300 mm) in a Pharmacia FPLC system. A 
linear gradient of increasing acetonitrile concentra- 
tion (0-100070) in 0.1070 TFA was applied and the 
M-CSF eluted at 46-48 min. The M-CSF was re- 
chromatographed on/z-Bondapak Cxs as above. 
2.3. Automated gas-phase Edman degradation 
and amino acid analysis 
An aliquot of the purified M-CSF (30/zg) was 
sequenced in an Applied Biosystems model 470A 
protein sequencer set in series with HPLC (Applied 
Biosystems model 120A). Aliquots (0.3/zg) of the 
purified M-CSF were separately hydrolyzed for 
21 h in 6 M HCI at l l0°C. The hydrolysate was 
derivatized with phenylthiocyanate and analyzed 
on HPLC equipped with a Pico-Tag amino-acid 
analysis column (Waiters). 
2.4. Assay of M-CSF and other methods 
The activity of M-CSF was measured as in [5]. 
Serial dilution of sample solutions was performed 
to determine the concentration giving about half- 
maximal number of macrophage colonies in 7-day 
cultures of 105 mouse bone marrow cells. One unit 
of M-CSF corresponds to one colony in such a 
culture as that above. 
Slab gel electrophoresis was carried out on a 
10070 polyacrylamide g l (7 × 8 cm) in the presence 
of 0.1070 SDS as described by Laemmli [6], the gel 
being silver-stained according to Merril et al. [7]. 
Protein concentrations were measured by the Bio- 
Rad dye-binding method [8]. 
3. RESULTS 
We purified an M-CSF from human urine to ap- 
parent homogeneity. Firstly, a partially purified 
preparation was obtained in 23°70 yield by a 5-step 
procedure at 5°C and stocked at -20°C without 
loss of activity. The preparation was further 
purified on the FPLC system with Superose-12 
(gel-permeation) and /z-Bondapak ClS (reverse- 
phase) columns. Table 1 summarizes the results on 
purification of M-CSF. 
The finally purified preparation (3/zg) gave a 
single band at an estimated molecular mass of 
82 kDa when electrophoresed in the presence of 
0.1070 SDS. Treatment of the preparation at 37°C 
for 10 min with 0.5070 SDS/1070 mercaptoethanol 
converted more than 90°70 of the protein to a 
species of 36 kDa. No other distinct band was 
found on the gel. 
An aliquot (30/~g) of the purified preparation 
was subjected to N-terminal sequence analysis. 
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Table 1 
Summary of purification of macrophage colony-stimulating factor from 
amount of normal human urine 
a large 
Step Protein M-CSF Recovery 
(mg) (070) 
Units Units/mg 
( X 10 -6) ( X 10 -3) 
1. Tokusil/ammonium sulfate 46300 833 18 100 
2. DEAE-cellulofine AH 21 100 950 45 114 
3. DE52 6110 489 80 59 
4. Phenyi-Sepharose CL-4B 240 264 1100 32 
5. Sephacryl $300 7.5 188 25000 23 
6. Superose-12 FPLC a 3.0 135 45000 16 
7./z-Bondapak C18 FPLC a 0.20 21 105000 2.5 
a Only portions of the active fraction were processed at steps 5 and 6. Data have been 
corrected for the portions that were not processed 
Table 2 
Amino acid composition of a macrophage colony-stimulating factor from normal human urine 
Amino Content b Number of residues based on 
acid a (mol per 
mol His) Sequence 1-154 (His = 4) Sequence 1-190 (His = 5) 
Present Deduced Deduced Present Deduced Deduced 
data MIA-PaCa TPA data M1A-PaCa TPA 
Ala 2.142 9 5 5 11 6 l 0 
Asx c 4.357 17 18 19 22 18 22 
Arg 1.250 5 6 5 6 7 5 
Glx c 4.428 18 27 25 22 31 25 
Gly 0.785 3 3 2 4 6 3 
His 1.000 4 4 3 5 5 4 
Ile 1.642 7 7 7 8 8 8 
Leu 3.964 16 16 16 20 24 19 
Lys 2.750 11 11 12 14 11 13 
Met a - (4) 4 4 (5) 4 5 
Phe 1.892 8 9 9 9 11 9 
Pro 2.428 10 3 3 12 5 11 
Ser 3.071 12 12 12 15 18 17 
Thr 2,142 9 8 9 11 8 11 
Tyr 1.000 4 5 5 5 6 6 
Val 2.250 9 8 10 11 12 13 
Trp d - (1) 1 1 (1) 2 1 
1/2 Cys a - (7) 7 7 (9) 7 9 
Total 154 154 154 190 190 190 
M, 17477 21558 
a Values are the averages of 3 independent determinations. Variation of the values was within _+ 10070 of 
average 
b Numbers in parentheses are the number of individual residues in the deduced sequence 1-154 
c Combined total of free acid and acid amide 
d Values for Met, Trp, and 1/2 Cys are taken from the paper of Wong et al. [3] 
each 
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Fig. 1. N-terminal amino acid sequence of human urine 
M-CSF. The yield of PhNCS amino acid at each cycle of 
automated Edman degradation is plotted vs cycle 
number. Small bars and plus signs represent the precycle 
and carry-over signals, respectively. The deduced 
sequence is shown in the upper part of the figure in the 
single-letter code. The arrow shows Ser at position 37. 
The yields of phenylthiohydantoin (PhNCS) 
amino acids at each cycle of Edman degradation 
are shown in fig.1 together with precycle signals 
and carry-over from the preceding cycle. The N- 
terminus was identified as Glu. There was no other 
PhNCS-amino acid peak at the first cycle, which 
was larger than 1/60 of the PhNCS-Glu peak. 
Table 2 lists the results of the amino acid 
analysis. The analytical values are expressed as mol 
individual amino acid per mol His, and the number 
of residues of each amino acid was calculated with 
respect o the integral value of His being 4 or 5. 
Table 2 also shows the number of amino acid 
residues present in the sequence deduced by other 
workers [2,3]. 
4. DISCUSSION 
The advanced method described above 
facilitates the large-scale purification of M-CSF 
from normal human urine. Homogeneity of the 
finally purified preparation was demonstrated by 
SDS gel electrophoresis as well as by the N- 
terminal amino acid analysis. 
The N-terminal amino acid sequence we deter- 
mined was consistent with that deduced by other 
workers [2,3] except for a single difference at posi- 
tion 37: we found Ser instead of Phe at this posi- 
tion. The replacement of Ser-37 by Phe can be 
explained by the change of the Ser codon to a Phe 
codon via a single base replacement in the eDNA 
clone. 
The amino acid composition of our M-CSF 
preparation most closely fits the sequence deduced 
by Wong et al. [3] when the integral value for each 
residue is calculated on the basis of the assumption 
that the molecule contains 5 His residues. On the 
other hand, the sequence deduced by Kawasaki et 
al. [2] does not match well with the result of our 
determination. Apparent discrepancy was noted 
with regard to the Glx, Ala and Pro contents. The 
results suggest hat the human urine M-CSF we 
purified carries, at its carboxyl terminus, a part of 
the intervening sequence that was deduced by 
Wong et al. [3]. 
The apparent molecular mass of the M-CSF was 
estimated to be 36 kDa by SDS gel electrophoresis, 
which is about 1.7-times larger than that estimated 
from the amino acid composition. This difference 
could arise from the carbohydrate content of the 
molecule. 
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